$5.72
2.14% yesterday
NYSE, Jun 13, 10:00 pm CET
ISIN
US04635X1028
Symbol
ATXS
Sector
Industry

Astria Therapeutics Stock price

$5.72
+1.82 46.67% 1M
-3.80 39.92% 6M
-3.22 36.02% YTD
-3.45 37.62% 1Y
-34.84 85.90% 5Y
-774.28 99.27% 10Y
-774.28 99.27% 20Y
NYSE, Closing price Fri, Jun 13 2025
+0.12 2.14%
ISIN
US04635X1028
Symbol
ATXS
Sector
Industry

Key metrics

Market capitalization $316.03m
Enterprise Value $20.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-124.40m
Free Cash Flow (TTM) Free Cash Flow $-96.14m
Cash position $295.06m
EPS (TTM) EPS $-1.88
P/E forward negative
Short interest 6.73%
Show more

Is Astria Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Astria Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Astria Therapeutics forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Astria Therapeutics forecast:

Buy
100%

Financial data from Astria Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
23% 23%
-
- Research and Development Expense 89 89
37% 37%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -124 -124
33% 33%
-
Net Profit -108 -108
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Astria Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Astria Therapeutics Stock News

Neutral
Business Wire
about 15 hours ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, i...
Neutral
Business Wire
8 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FR...
Neutral
Business Wire
10 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria's common stock on June 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant o...
More Astria Therapeutics News

Company Profile

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jill Milne
Employees 78
Founded 2008
Website astriatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today